Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

Inclusion Criteria:

• Signed informed consent must be obtained prior to participation in the study.

• Dose escalation and dose expansion group 1:

Patients with histologically or cytologically confirmed diagnosis of advanced (metastatic or unresectable) NFE2L2/KEAP1/CUL3 mutant NSCLC. Local data confirming the NFE2L2/KEAP1/CUL3 mutation status in tissue must be available for enrollment.

• Dose expansion group 2:

Patients with histologically or cytologically confirmed diagnosis of advanced (metastatic or unresectable) NSCLC irrespective of NFE2L2/KEAP1/CUL3 mutation status.

• All patients:

Patients must have progressed after 1 platinum-based chemotherapy regimen and PD-(L)1 antibody therapy either sequentially or concurrent with chemotherapy, where indicated, for Stage IV NSCLC.

Patients treated with neo-adjuvant / adjuvant platinum-based therapy that progressed within 6 months of treatment are permitted to participate.

Prior therapy with VEGF/VEGFR targeting agents is permitted. Prior treatment with approved targeted drugs (e.g., EGFRi, ALKi, METi) is mandatory in patients with NSCLC whose tumor bears actionable mutations.

• Presence of at least one measurable lesion according to RECIST v1.1.

• Patient must have a site of disease amenable to biopsy and be a candidate for tumorbiopsy according to the treating institution's guidelines. Patient must be willingto undergo a new tumor biopsy at screening and during study treatment. A recentbiopsy collected after the last systemic treatment and within 3 months before studyentry may be submitted at screening.

Exclusion Criteria:

• Having out of range laboratory values defined as:

Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 60 mL/min Total bilirubin > 1.5 x ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN ALT > 3 x ULN AST > 3 x ULN ANC < 1.0 x 109/L Platelet count < 75 x 109/L Hemoglobin < 9 g/dL

• Impaired cardiac function or clinically significant cardiac disease, including anyof the following:

Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment (NYHA Grade ≥2), uncontrolled hypertension or clinically significant arrhythmia.

QTcF > 470 msec on screening ECG or congenital long QT syndrome. Acute myocardial infarction or unstable angina pectoris < 3 months prior to study entry.

• Presence of symptomatic CNS metastases, or CNS metastases that require localCNS-directed therapy (such as radiotherapy or surgery) or increasing doses ofcorticosteroids within 2 weeks prior to study entry. Patients with treatedsymptomatic brain metastases should be neurologically stable (for 4 weekspost-treatment and prior to study entry) and at a dose of ≤ 10 mg per day prednisoneor equivalent for at least 2 weeks before administration of any study treatment.

• Known active COVID-19 infection.

• Unable or unwilling to swallow capsules as per dosing schedule. Otherprotocol-defined inclusion/exclusion criteria may apply.